Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and TS-1 in Advanced Biliary Tract Cancer
NCT01171755Phase 2Terminated
- Sponsor
- Samsung Medical Center
- Start
- Feb 2008
- Primary completion
- Dec 2009
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of tegafur in biliary tract cancer (BTC), sponsored by Samsung Medical Center. Primary endpoint: Response rate at 1.5 years. Started Feb 2008; status: terminated.
02
Drugs
tegafur
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT01171755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01171755.